SEC inhibitor KL-1 (Synonyms: KL-1) |
| Catalog No.GC38063 |
펩티드모방 납 화합물인 SEC 억제제 KL-1(KL-1)은 강력한 선택적 초신장 복합체(SEC) 억제제이며 SEC 스캐폴딩 단백질 AFF4와 P-TEFb 사이의 상호작용을 방해하여 Pol II의 방출을 손상시킵니다. 프로모터-근위 정지 부위 및 감소된 평균 진행성 전사 신장률. SEC 억제제 KL-1은 3.48μM의 Ki로 AFF4-CCNT1 상호작용에 대한 용량 의존적 억제 효과를 나타낸다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 900308-84-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SEC inhibitor KL-1 (KL-1), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) inhibitor and disrupts the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC inhibitor KL-1 exhibits an dose-dependent inhibitory effect on AFF4-CCNT1 interaction with a Ki of 3.48 μM[1].
[1]. Liang K, et al. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced CancerTherapy. Cell. 2018 Oct 18;175(3):766-779.
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *